Developments in the management and treatment of pulmonary embolism

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 484-497

  Limbrey, Rachel ^a   Howard, Luke ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; APIXABAN; D DIMER; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLOOD CLOT LYSIS; CANCER PROGNOSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART RIGHT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMAGING; INTERMEDIATE RISK PATIENT; LABORATORY TEST; LOW RISK PATIENT; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHOCK; SINGLE DRUG DOSE; TREATMENT DURATION; BLEEDING; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHEMICALLY INDUCED; CLINICAL PATHWAY; DECISION TREE; DRUG EFFECTS; DRUG MONITORING; MORTALITY; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; PROCEDURES; PULMONARY EMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CRITICAL PATHWAYS; DECISION TREES; DRUG MONITORING; HEMORRHAGE; HUMANS; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84940644489     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00006614     Document Type: Review

References (84)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–764.
2. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276–2315.
3. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92–96.
4. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–2264.
5. Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75: 1249–1256.
6. Baldwin MJ, Moore HM, Rudarakanchana N, et al. Post-thrombotic syndrome: a clinical review. J Thromb Haemost 2013; 11: 795–805.
7. Kröger K, Küpper-Nybelen J, Moerchel C, et al. Prevalence and economic burden of pulmonary embolism in Germany. Vasc Med 2012; 17: 303–309.
8. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: Suppl. 2, 7S–47S.
9. National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE guidelines CG144. http://guidance.nice.org.uk/CG144 Date last updated: June 2012. Date last accessed: July 22 2014.
10. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–3073.
11. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037–1052.
12. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: Suppl. 2, e419S–e494S.
13. Blann AD, Lip GYH. Venous thromboembolism. BMJ 2006; 332: 215–219.
14. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383–1389.
15. Bova C, Sanchez O, Prandoni P, et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; 44: 694–703.
16. Becattini C, Agnelli G, Germini F, et al. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J 2014; 43: 1678–1690.
17. Fesmire FM, Brown MD, Espinosa JA, et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism. Ann Emerg Med 2011; 57: 628–652.
18. Lankeit M, Jiménez D, Kostrubiec M, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43: 1669–1677.
19. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416–420.
20. Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008; 168: 2131–2136.
21. van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295: 172–179.
22. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med 2007; 5: 63–73.
23. Geersing GJ, Erkens PM, Lucassen WA, et al. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ 2012; 345: e6564.
24. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: Suppl. 1, I22–I30.
25. Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol 2013; 111: 273–277.
26. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479–486.
27. Kline J, Hernandez J, Kabrhel C, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient-oriented cardiopulmonary outcomes at three months. J Am Coll Cardiol 2013; 61: Suppl. 10, Abstract 932-8, DOI:10.1016/S0735-1097(13)62074-4.
28. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370: 1402–1411.
29. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523–1532.
30. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.
31. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.
32. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
33. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.
34. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.
35. Zahir H, Matsushima N, Halim AB, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost 2012; 108: 166–175.
36. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf Date last updated: May 15, 2015. Date last accessed: June 26, 2015.
37. Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (apixaban) Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf Date last updated: September 29, 2014. Date last accessed: June 26, 2015.
38. Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf Date last updated: February 18, 2015. Date last accessed: June 26, 2015.
39. Bristol-Myers Squibb. Coumadin (warfarin sodium) Prescribing Information. http://packageinserts.bms.com/pi/pi_coumadin.pdf Date last updated: October, 2011. Date last accessed: October 6, 2014.
40. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013; 34: 489–498.
41. Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242–2247.
42. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180–187.
43. Mueck W, Lensing AWA, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675–686.
44. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764–772.
45. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458–462.
46. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011; 342: d3036.
47. Poli D, Miniati M. The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. Curr Opin Pulm Med 2011; 17: 392–397.
48. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis – current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824–833.
49. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813.
50. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121: 1630–1636.
51. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019–1025.
52. Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8: 1216–1222.
53. Nijkeuter M, Söhne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest 2007; 131: 517–523.
54. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
55. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809–815.
56. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.
57. Prins MH, Lensing AWA, Brighton TA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1: e37–e46.
58. Prins MH, Lensing AWA, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
59. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970–979.
60. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91–99.
61. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13: 311–316.
62. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709–718.
63. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
64. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–1967.
65. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–1987.
66. Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9: 1500–1507.
67. Desai SR. Unsuspected pulmonary embolism on CT scanning: yet another headache for clinicians? Thorax 2007; 62: 470–472.
68. Goodman LR. Small pulmonary emboli: what do we know? Radiology 2005; 234: 654–658.
69. Stein PD, Goodman LR, Hull RD, et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost 2012; 18: 20–26.
70. den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood 2013; 122: 1144–1149.
71. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378: 41–48.
72. McCabe A, Hassan T, Doyle M, et al. Identification of patients with low-risk pulmonary embolism suitable for outpatient treatment using the pulmonary embolism severity index (PESI). Ir J Med Sci 2013; 182: 291–295.
73. Kovacs MJ, Hawel JD, Rekman JF, et al. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost 2010; 8: 2406–2411.
74. Erkens PM, Gandara E, Wells PS, et al. Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? Thromb Res 2012; 129: 710–714.
75. Zondag W, Kooiman J, Klok FA, et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013; 42: 134–144.
76. Otero R, Uresandi F, Jiménez D, et al. Home treatment in pulmonary embolism. Thromb Res 2010; 126: e1–e5.
77. Stein PD, Beemath A, Matta F, et al. Enlarged right ventricle without shock in acute pulmonary embolism: prognosis. Am J Med 2008; 121: 34–42.
78. Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood 2012; 119: 1561–1565.
79. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880–888.
80. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med 2011; 6: 113–116.
81. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor Xa. Nat Med 2013; 19: 446–451.
82. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554–3562.
83. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013; 11: 10.
84. National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261. www.nice.org.uk/ta261 Date last updated: July, 2012. Date last accessed: October 6, 2014.